Lymphoma: all 5,623 studies
Page 4 of 57. Open to participants first (823), then studies with results posted, then the rest; newest registration first within each.
- An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingNCT06517004Phase 1
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
- Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone LymphomasRecruitingNCT06513234Phase 2
- Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront ChemoimmunotherapyRecruitingNCT06510361Phase 2
- Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaRecruitingNCT06510309Phase 2
- Vitamin A and D Supplementation in Allogeneic HCTRecruitingNCT06508099Phase 2
- The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and RadiotherapyRecruitingNCT06503276Phase 2
- Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCLRecruitingNCT06503263Phase 2
- A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.RecruitingNCT06497452
- Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingNCT06496308Phase 3
- A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell LymphomaRecruitingNCT06494371Phase 1
- Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLRecruitingNCT06489808Phase 2
- HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable
- CAR-T-cell Treatment for Untreated High Risk MANtle Cell LymphomaRecruitingNCT06482684Phase 2
- CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell LymphomaRecruitingNCT06479356Phase 2
- Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyRecruitingNCT06478472Not applicable
- L218CAR19 in Patients With Relapsed/Refractory B-cell LymphomaRecruitingNCT06478381Phase 1
- Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLRecruitingNCT06475235Phase 1
- Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular LymphomaNot yet recruitingNCT06474481Phase 2
- Virus-associated Tumour MicroenvironmentRecruitingNCT06471296
- RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL.RecruitingNCT06468267Phase 2
- A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin LymphomaNot yet recruitingNCT06465446Phase 3
- Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell LymphomaRecruitingNCT06464861Phase 1
- Ga-68-CXCR4 PET/CT in Indolent B-cell LymphomaRecruitingNCT06461182Phase 2
- Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
- CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHLRecruitingNCT06445803Phase 1
- A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLRecruitingNCT06445257Not applicable
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsRecruitingNCT06441331Phase 1
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
- A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell LymphomaRecruitingNCT06436677
- The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic LymphomaNot yet recruitingNCT06434467Phase 3
- CMOEP in the Treatment of Untreated Peripheral T-cell LymphomaRecruitingNCT06433362Phase 2
- This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaNot yet recruitingNCT06427213Phase 2
- CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT06420089Phase 1
- Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T CellsRecruitingNCT06420076Phase 1/2
- Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaRecruitingNCT06415708Phase 2
- MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaRecruitingNCT06414148Phase 2
- A Prospective Study: Sintilimab and R-CHOP in PMBCL TreatmentNot yet recruitingNCT06412068Phase 2
- Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation.RecruitingNCT06409767Not applicable
- Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTLRecruitingNCT06406556Phase 2
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06395870Phase 1
- Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCLRecruitingNCT06382844
- Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaRecruitingNCT06376721Phase 1/2
- Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer SurvivorsRecruitingNCT06371768Not applicable
- A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular LymphomaNot yet recruitingNCT06368167Phase 2
- MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLNot yet recruitingNCT06367374Phase 2
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Phase 3
- CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+RecruitingNCT06355739Not applicable
- Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?RecruitingNCT06352242Not applicable
- Mediastinal EBUS Cryobiopsy Study In SwedenRecruitingNCT06347939
- A National Multicenter, Real-world Study of Linperlisib in the Treatment of LymphomaNot yet recruitingNCT06343935Phase 4
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)RecruitingNCT06343311Phase 1/2
- A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell LymphomaRecruitingNCT06341556Phase 2
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasRecruitingNCT06340737Phase 1
- Risk Adapted Therapy of Hodgkin Lymphoma in Upper EgyptNot yet recruitingNCT06340243
- Italian Observational Study on CAR-T Therapy for LymphomaRecruitingNCT06339255
- CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological MalignanciesRecruitingNCT06326463Phase 1
- Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.Not yet recruitingNCT06324994Phase 2
- TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell LymphomaRecruitingNCT06323525Phase 1/2
- Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHLRecruitingNCT06321289Phase 1/2
- A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT06318884Phase 1
- A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHLNot yet recruitingNCT06314828Phase 1
- A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06313957Phase 1
- PTCy and ATG for MSD and MUD TransplantsRecruitingNCT06299462Phase 1/2
- DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology ClinicsRecruitingNCT06296368Not applicable
- AGMT Austrian Lymphoma RegistryRecruitingNCT06294652
- Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPIRecruitingNCT06290817Phase 2
- Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCLNot yet recruitingNCT06289959Not applicable
- Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCLRecruitingNCT06287398Phase 2
- Effects of Exercise Training in Survivors of LymphomaRecruitingNCT06270667Not applicable
- Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.RecruitingNCT06263361
- RAT-HEMATO : Return to Work After Malignant HemopathyRecruitingNCT06262789Not applicable
- The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell LymphomaNot yet recruitingNCT06255795Phase 3
- GVM±R in Patients With Relapsed or Refractory Aggressive NHL.RecruitingNCT06244368Phase 2
- Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T TherapyRecruitingNCT06238648Phase 2
- Orelabrutinib in the Treatment of HP-positive Gastric MALT LymphomaRecruitingNCT06228963Phase 2
- Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITLRecruitingNCT06224842Phase 1/2
- Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-TRecruitingNCT06224049Early Phase 1
- Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.RecruitingNCT06218602Phase 2
- Chi-GVM Regimen for the Treatment of R/R PTCLRecruitingNCT06211881Not applicable
- Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent CancerRecruitingNCT06208657Phase 1/2
- F01 in the Treatment of Relapsed/Refractory Non-hodgkin's LymphomaRecruitingNCT06206902Phase 1
- The Pathogenesis and Prognostic Factors of LymphomaRecruitingNCT06203652
- BV-AVD-R Treatment Children Hodgkin's LymphomaEnrolling by invitationNCT06201507Phase 2
- Digital Peer Navigation for Adolescents and Young Adults With CancerRecruitingNCT06193369Not applicable
- Azacitidine Plus PD-1 Therapy for R/R Hodgkin LymphomaRecruitingNCT06190067Phase 2
- CD30 Imaging in Diffuse Large B-cell LymphomaNot yet recruitingNCT06186986Phase 3
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell LymphomaRecruitingNCT06180174Phase 1
- Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell LymphomasRecruitingNCT06176027Phase 1/2
- A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell LymphomaRecruitingNCT06173999Phase 1/2
- A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)RecruitingNCT06170489Phase 3
- Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06164327Phase 1
- Characterization and Clinical Impact of the Gut Microbiota in LymphomaRecruitingNCT06161896
- The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)RecruitingNCT06160362Not applicable
- AZA Combined With RCHOP in P53-mutated DLBCL.RecruitingNCT06158399Phase 2
- Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular LymphomaRecruitingNCT06158386Phase 2
- Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FLRecruitingNCT06151080Phase 2
- Relmacabtagene Autoleucel in Hematologic MalignanciesNot yet recruitingNCT06142188
- Relmacabtagene Autoleucel in Patients With LBCLRecruitingNCT06142175